Latest news

Media
Latest news
Newsletters

Media

Mycompanypolska.pl: Bioceltix will obtain almost PLN 53 million for the construction of a new stem cell factory

As a result of the successful share offering, we will raise nearly PLN 53 million. These funds will be used,...

Read more

Puls Biznesu: Funding needed for dog medications. Bioceltix seeks capital again

Dr. Paweł Wielgus, Eng., spoke with Puls Biznesu about current plans to raise capital for the construction of a new...

Read more

Telewizja Biznesowa: Bioceltix – from a startup to a million-dollar company

During the Wall Street in Karpacz, Dr. Paweł Wielgus, Eng., spoke with Telewizja Biznesowa about our journey from idea to...

Read more

Parkiet.com: Pessimism around biotechnology is absurdly high. Will the tide turn?

This is an important time for Polish biotechnology. Despite geopolitical turmoil, many companies are increasingly close to breakthroughs and commercialization...

Read more

Gazeta Wyborcza: Veterinary Medicine. The largest stem cell factory will be created in Wrocław.

Veterinary biotechnology has the potential to revolutionize the current approach to animal treatment, increasing effectiveness and reducing side effects, says...

Read more

Puls Biznesu: Dog medicines are heating up Bioceltix

Dog medications are heating up Bioceltix, we read in Puls Biznesu. The same goes for the results of this year’s...

Read more

Latest news

Bioceltix’s share offering is a success. The company will raise nearly PLN 53 million to build a new stem cell facility.

Bioceltix will raise nearly PLN 53 million gross, among other things, for the construction of a plant for veterinary medicinal...

Read more

Bioceltix SA shareholders have approved the share issue. The company plans to raise approximately PLN 45 million for the construction of a new stem cell facility.

Bioceltix, a publicly traded biotechnology company with a veterinary profile, received shareholder support for an issue of up to 457,000...

Read more

Bioceltix S.A. plans to finance part of the costs of the ongoing construction of a pharmaceutical plant through the issue of shares

A publicly traded biotechnology company developing veterinary medicines for companion animals is working with contracted subcontractors to build a large-scale...

Read more

Bioceltix SA announces the success of a clinical trial of a product for atopic dermatitis in dogs. The company is one step closer to registering a breakthrough drug.

A veterinary biotech company listed on the Warsaw Stock Exchange (GPW) has published the final results of a clinical trial...

Read more

Bioceltix is ​​initiating the registration process for a drug for equine arthritis. The company has submitted an application to the European Medicines Agency.

Another important milestone in the history of Bioceltix. The publicly traded veterinary company has submitted an application to the European...

Read more

Bioceltix announces success in clinical trial of equine arthritis product. Company one step closer to registration and commercialization of breakthrough drug

A veterinary biotechnology company listed on the Warsaw Stock Exchange (GPW) has published the full results of a clinical trial...

Read more

Newsletters

PLN 53 million for strategy implementation and construction of a new production plant

Good morning, Poland is a leading pet-friendly country. According to a FEDIAF report, the percentage of households with at least...

Read more
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.